{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:04:22Z","timestamp":1792260262132,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"crossref","award":["100CM-KMU-09, KMU-KI110002, MOST 108-2314-B-037 -066 -MY3, KMU-TC109B05 [Center for Liquid Biopsy and Cohort Research], KMU-TC109A04 [Center for Cancer Research]"],"award-info":[{"award-number":["100CM-KMU-09, KMU-KI110002, MOST 108-2314-B-037 -066 -MY3, KMU-TC109B05 [Center for Liquid Biopsy and Cohort Research], KMU-TC109A04 [Center for Cancer Research]"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH109-9R06, KMUH-DK(C)110011, KMUH-DK(C)110004, KMUH109-9R05"],"award-info":[{"award-number":["KMUH109-9R06, KMUH-DK(C)110011, KMUH-DK(C)110004, KMUH109-9R05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The study evaluated the real-world treatment outcomes of Glecaprevir\/pibrentasvir (GLE\/PIB) including effectiveness, safety and healthcare resource utilization based on a nation-wide registry in Taiwan. The Taiwan HCV Registry <jats:bold>(<\/jats:bold>TACR) is a nation-wide platform organized and supervised by the Taiwan Association for the Study of the Liver. Data were analyzed for patients treated with GLE\/PIB, including 3144 patients who had treatment outcome available. The primary endpoint was sustained virological response (SVR12, undetectable HCV RNA throughout 12\u00a0weeks of end-of-treatment). The overall SVR12 rate was 98.9% (3110\/3144), with 98.8%, 99.4% and 100% in patients receiving 8\u00a0weeks, 12\u00a0weeks, and 16\u00a0weeks of GLE\/PIB respectively. The SVR12 rate in the treatment-na\u00efve cirrhotic patients receiving 8\u00a0weeks of GLE\/PIB was 98.2% (108\/110). The most common AEs were fatigue (7.5%), pruritus (6.7%) and dizziness (1.5%). The mean number of outpatient visits during the GLE\/PIB was 5.94 visits for patients treated with 8\u00a0weeks, significantly different from the patients treated with 12\u00a0weeks of GLE\/PIB (6.90 visits). The results support the effectiveness and safety of GLE\/PIB treatment in real-world clinical practice, and provide further evidence that the shorter, 8-week GLE\/PIB regimen is effective and cost-saving.<\/jats:p>","DOI":"10.1038\/s41598-021-03006-3","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T11:06:05Z","timestamp":1638788765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan"],"prefix":"10.1038","volume":"11","author":[{"given":"Chung-Feng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Tao","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chu","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Won","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Nan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jong","family":"Bair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Lang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chieh","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Yuan","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzong-Hsi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chih","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Shun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Ting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lein-Ray","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guei-Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Neng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Hsuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chih","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"3006_CR1","unstructured":"World Health Organization, Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. WHO, https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO?sequence=1. Accessed 27 June 2021."},{"key":"3006_CR2","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1097\/MD.0000000000000690","volume":"94","author":"ML Yu","year":"2015","unstructured":"Yu, M. L. et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine 94, e690 (2015).","journal-title":"Medicine"},{"key":"3006_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1607-551X(10)70073-5","volume":"26","author":"JF Yang","year":"2010","unstructured":"Yang, J. F. et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J. Med. Sci. 26, 461\u2013469 (2010).","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"1","key":"3006_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/kjm2.12345","volume":"37","author":"ML Yu","year":"2021","unstructured":"Yu, M. L. & Chuang, W. L. Path from the discovery to the elimination of hepatitis C virus: honoring the winners of the Nobel Prize in Physiology or Medicine 2020. Kaohsiung J. Med. Sci. 37(1), 7\u201311 (2021).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"3006_CR5","unstructured":"https:\/\/www.nhi.gov.tw\/Content_List.aspx?n=A4EFF6CD1C4891CA&topn=3FC7D09599D25979. Accessed 10 Feb 2021."},{"key":"3006_CR6","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jfma.2020.04.003","volume":"119","author":"ML Yu","year":"2020","unstructured":"Yu, M. L. et al. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. J. Formosan Med. Assoc. 119, 1019\u20131040 (2020).","journal-title":"J. Formosan Med. Assoc."},{"issue":"7","key":"3006_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jfma.2020.04.002","volume":"119","author":"ML Yu","year":"2020","unstructured":"Yu, M. L. et al. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. J. Formosan Med. Assoc. 119(7), 1135\u20131157 (2020).","journal-title":"J. Formosan Med. Assoc."},{"issue":"3","key":"3006_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","volume":"72","author":"RS Brown","year":"2020","unstructured":"Brown, R. S. et al. Glecaprevir\/pibrentasvir for 8 weeks in treatment-na\u00efve patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: The EXPEDITION-8 trial. J. Hepatol. 72(3), 441\u2013449 (2020).","journal-title":"J. Hepatol."},{"key":"3006_CR9","unstructured":"AbbVie Inc. MAVIRET (glecaprevir\/pibrentasvir) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/maviret. Accessed 10 Feb 2021."},{"issue":"2","key":"3006_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","volume":"69","author":"M Puoti","year":"2018","unstructured":"Puoti, M. et al. High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1\u20136 patients without cirrhosis. J. Hepatol. 69(2), 293\u2013300 (2018).","journal-title":"J. Hepatol."},{"issue":"10","key":"3006_CR11","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/cid\/ciz022","volume":"69","author":"E Gane","year":"2019","unstructured":"Gane, E. et al. Safety and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1\u20136 hepatitis C virus infections and compensated liver disease. Clin. Infect. Dis. 69(10), 1657\u20131664 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"3006_CR12","first-page":"e026703","volume":"9","author":"CF Huang","year":"2019","unstructured":"Huang, C. F. et al. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma?. A prospective cohort study. BMJ Open 9, e026703 (2019).","journal-title":"A prospective cohort study. BMJ Open"},{"key":"3006_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/liv.14295","volume":"40","author":"CH Liu","year":"2020","unstructured":"Liu, C. H., Liu, C. J. & Hung, C. C. Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. Liver Int. 40, 758\u2013768 (2020).","journal-title":"Liver Int."},{"issue":"8","key":"3006_CR14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jfma.2019.06.014","volume":"118","author":"SJ Hsu","year":"2019","unstructured":"Hsu, S. J. et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir in Asian patients with chronic hepatitis C. J. Formosan Med. Assoc. 118(8), 1187\u20131192 (2019).","journal-title":"J. Formosan Med. Assoc."},{"key":"3006_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14849","author":"CY Chen","year":"2021","unstructured":"Chen, C. Y. et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. https:\/\/doi.org\/10.1111\/liv.14849 (2021).","journal-title":"Liver Int."},{"issue":"3","key":"3006_CR16","first-page":"1","volume":"2013","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013(3), 1\u201315 (2012).","journal-title":"Kidney Int. Suppl."},{"issue":"6","key":"3006_CR17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","volume":"72","author":"P Lampertico","year":"2020","unstructured":"Lampertico, P. et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. J. Hepatol. 72(6), 1112\u20131121 (2020).","journal-title":"J. Hepatol."},{"issue":"4","key":"3006_CR18","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/infdis\/162.4.817","volume":"162","author":"DS Chen","year":"1990","unstructured":"Chen, D. S. et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J. Infect. Dis. 162(4), 817\u2013822 (1990).","journal-title":"J. Infect. Dis."},{"key":"3006_CR19","doi-asserted-by":"publisher","DOI":"10.5009\/gnl19393","author":"YJ Park","year":"2020","unstructured":"Park, Y. J. et al. Real-life effectiveness and safety of glecaprevir\/pibrentasvir for Korean patients with chronic ephatitis C at a single institution. Gut Liver https:\/\/doi.org\/10.5009\/gnl19393 (2020).","journal-title":"Gut Liver"},{"key":"3006_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3350\/cmh.2020.0018","volume":"26","author":"CF Huang","year":"2020","unstructured":"Huang, C. F. & Yu, M. L. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy. Clin. Mol. Hepatol. 26, 251\u2013260 (2020).","journal-title":"Clin. Mol. Hepatol."},{"key":"3006_CR21","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","volume":"377","author":"E Gane","year":"2017","unstructured":"Gane, E. et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N. Engl. J. Med. 377, 1448\u20131455 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"3006_CR22","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1111\/liv.14170","volume":"39","author":"M Persico","year":"2019","unstructured":"Persico, M. et al. Real-life glecaprevir\/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. Liver Int. 39(10), 1852\u20131859 (2019).","journal-title":"Liver Int."},{"key":"3006_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15337","author":"D Zar\u0119bska-Michaluk","year":"2020","unstructured":"Zar\u0119bska-Michaluk, D. et al. Is an 8-week regimen of glecaprevir\/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?. J. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1111\/jgh.15337 (2020).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"3","key":"3006_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","volume":"70","author":"R D\u2019Ambrosio","year":"2019","unstructured":"D\u2019Ambrosio, R. et al. Real-world effectiveness and safety of glecaprevir\/ pibrentasvir in 723 patients with chronic hepatitis C. J. Hepatol. 70(3), 379\u2013387 (2019).","journal-title":"J. Hepatol."},{"key":"3006_CR25","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.dld.2020.08.007","volume":"53","author":"A Aghemo","year":"2020","unstructured":"Aghemo, A. et al. Effectiveness and safety of glecaprevir\/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Digestive Liver Dis. 53, 612\u2013619 (2020).","journal-title":"Digestive Liver Dis."},{"issue":"9","key":"3006_CR26","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1007\/s12325-020-01449-0","volume":"37","author":"P Lampertico","year":"2020","unstructured":"Lampertico, P. et al. Real-world clinical practice use of 8-week glecaprevir\/pibrentasvir in treatment-na\u00efve patients with compensated cirrhosis. Adv. Therapy 37(9), 4033\u20134042 (2020).","journal-title":"Adv. Therapy"},{"issue":"5","key":"3006_CR27","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/liv.14829","volume":"41","author":"H Wedemeyer","year":"2021","unstructured":"Wedemeyer, H. et al. Glecaprevir\/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry. Liver Int. 41(5), 949\u2013955 (2021).","journal-title":"Liver Int."},{"issue":"05","key":"3006_CR28","first-page":"e159","volume":"57","author":"M Gschwantler","year":"2019","unstructured":"Gschwantler, M. et al. Health related quality of life and healthcare resource utilization in chronic HCV patients under the glecaprevir\/pibrentasvir regimen: interim-analysis of the Austrian CONFIRMATION study. Z. Gastroenterol. 57(05), e159 (2019).","journal-title":"Z. Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03006-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T17:51:55Z","timestamp":1670089915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03006-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3006"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03006-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,6]]},"assertion":[{"value":"7 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23473"}}